120 related articles for article (PubMed ID: 32940081)
21. Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Di Molfetta S; Dotto A; Fanciulli G; Florio T; Feola T; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():667784. PubMed ID: 33935977
[TBL] [Abstract][Full Text] [Related]
22. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
23. Phosphorylation of signal transducer and activator of transcription 6 (STAT6) and STAT1, but not STAT3, induced by antigen inhalation in bronchial smooth muscles of sensitized mice.
Chiba Y; Todoroki M; Misawa M
Biol Pharm Bull; 2010; 33(1):146-9. PubMed ID: 20045954
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
25. Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer.
Aghajani MJ; Yang T; McCafferty CE; Graham S; Wu X; Niles N
Surgery; 2018 Jan; 163(1):130-136. PubMed ID: 29128181
[TBL] [Abstract][Full Text] [Related]
26. [Impact of STAT6 signaling pathway blockade on apoptosis of human colon cancer cells].
Zhang MS; Zhou YF; Xie CH; Zhang WJ; Zhou FX; Qu XJ
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):76-81. PubMed ID: 16620708
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.
Fan J; Shen X; Wang Y; Zhou HL; Liu G; Li YL; Xu ZX
Biomed Pharmacother; 2020 Oct; 130():110621. PubMed ID: 34321165
[TBL] [Abstract][Full Text] [Related]
28. The roles of STAT6 in regulating B cell fate, activation, and function.
Wang W; Wang L; Zha B
Immunol Lett; 2021 May; 233():87-91. PubMed ID: 33662403
[TBL] [Abstract][Full Text] [Related]
29. Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non- small-cell lung cancer.
Pastuszak-Lewandoska D; Domańska-Senderowska D; Kordiak J; Antczak A; Czarnecka KH; Migdalska-Sęk M; Nawrot E; Kiszałkiewicz JM; Brzeziańska-Lasota E
Pol Arch Intern Med; 2017 Nov; 127(11):758-764. PubMed ID: 28972958
[TBL] [Abstract][Full Text] [Related]
30. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
31. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
32.
Tan KT; Yeh CN; Chang YC; Cheng JH; Fang WL; Yeh YC; Wang YC; Hsu DS; Wu CE; Lai JI; Chang PM; Chen MH; Lu ML; Chen SJ; Chao Y; Hsiao M; Chen MH
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32238472
[TBL] [Abstract][Full Text] [Related]
33. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitors in AML-A New Frontier.
Thummalapalli R; Knaus HA; Gojo I; Zeidner JF
Curr Cancer Drug Targets; 2020; 20(7):545-557. PubMed ID: 32316893
[TBL] [Abstract][Full Text] [Related]
35. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
Bhalla S; Doroshow DB; Hirsch FR
Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
[TBL] [Abstract][Full Text] [Related]
36. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
37. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
Noguchi E; Shien T; Iwata H
Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
[TBL] [Abstract][Full Text] [Related]
38. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.
Todaro M; Zerilli M; Ricci-Vitiani L; Bini M; Perez Alea M; Maria Florena A; Miceli L; Condorelli G; Bonventre S; Di Gesù G; De Maria R; Stassi G
Cancer Res; 2006 Feb; 66(3):1491-9. PubMed ID: 16452205
[TBL] [Abstract][Full Text] [Related]
39. Apoptotic cells trigger the ABCA1/STAT6 pathway leading to PPAR-γ expression and activation in macrophages.
Kim MJ; Lee YJ; Yoon YS; Kim M; Choi JH; Kim HS; Kang JL
J Leukoc Biol; 2018 May; 103(5):885-895. PubMed ID: 29603355
[TBL] [Abstract][Full Text] [Related]
40. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Olbryt M; Rajczykowski M; Widłak W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
